First human iPSC-derived SENSORY NEURONS - Recruiting  BETA TESTERS - APPLY NOW 

The availability of in vitro differentiated human sensory neurons is crucial to study human physiology of pain, for disease modeling of pain and sensory dysfunctions, as well as for in vitro screening and target validation in drug discovery for analgesic drugs.

Axiogenesis has developed iPSC-derived sensory neurons, called Sensory.4U, which express functional TRP (transient receptor potential) nociceptors including TRPA1, TRPV1 and TRPM8. Thus, they are capable of sensation of hot and spice (capsaicin and OLDA reactivity), pungency (reactivity to mustard oil) and cold (reactivity to menthol). In contrast to currently available cell systems for studying sensory neuron function, in particular primary DRG cultures, Sensory.4U are derived from human iPS cells and are going to be available in unlimited quantities of reproducible quality, which facilitates testing of large compound libraries. These characteristics make Sensory.4U a key tool for sensory and pain related applications in research and drug discovery.

Axiogenesis is now looking for beta testers for early development to drive customer specific characterization of the Sensory.4U cells. Please reach out to This email address is being protected from spambots. You need JavaScript enabled to view it. if you want to apply to participate in our beta testing program

Peri4U MEA TRP channelsSensory.4U have functional TRPV1 and TRPA1 channels. Sensory.4U activity measured on MEA chips is increased through activation of TRPV1 (A) or TRPA1 (B) using the agonists as indicated. Arrows mark addition of agonist.



Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)




Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter


Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10